Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Net Income towards Common Stockholders (2016 - 2025)

Immucell (ICCC) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with -$139749.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income towards Common Stockholders rose 80.08% year-over-year to -$139749.0, compared with a TTM value of $2.3 million through Sep 2025, up 160.97%, and an annual FY2024 reading of -$2.2 million, up 62.65% over the prior year.
  • Net Income towards Common Stockholders was -$139749.0 for Q3 2025 at Immucell, down from $501881.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.4 million in Q1 2025 and bottomed at -$2.3 million in Q1 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$460301.4, with a median of -$441303.0 recorded in 2021.
  • The sharpest move saw Net Income towards Common Stockholders crashed 2349.8% in 2022, then skyrocketed 430.46% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at $74134.0 in 2021, then plummeted by 2349.8% to -$1.7 million in 2022, then surged by 31.66% to -$1.1 million in 2023, then skyrocketed by 145.14% to $514555.0 in 2024, then plummeted by 127.16% to -$139749.0 in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for ICCC at -$139749.0 in Q3 2025, $501881.0 in Q2 2025, and $1.4 million in Q1 2025.